Xia Peng, Gu Rui, Zhang Wei, Sun Yi-Fu
Department of Orthopaedics, Second Hospital of Jilin University, Changchun 130041, P.R. China.
Department of Orthopaedics, China-Japan Union Hospital of Jilin University, Changchun 130033, P.R. China.
Mol Ther Nucleic Acids. 2020 Mar 6;19:1470-1481. doi: 10.1016/j.omtn.2019.10.017. Epub 2019 Oct 24.
Osteosarcoma (OS) is the most common primary bone malignancy derived from primitive bone-forming mesenchymal cells. Long noncoding RNA (lncRNA) expression profiles have been intensively studied for their involvement in OS. Herein, we clarify whether lncRNA CEBPA-AS1 is a regulator of NCOR2 in OS cells. Microarray-based expression analysis identified OS-related differentially expressed lncRNA and predicted microRNAs (miRs) binding to lncRNA and mRNA. lncRNA CEBPA-AS1 and NCOR2 were found to be weakly expressed in OS tissues and cells. Next, functional investigation revealed that lncRNAs CEBPA-AS1 bound to miR-10b-5p to upregulate NCOR2. Following that, gene-targeted knockdown and overexpressed recombinant vectors of lncRNA CEBPA-AS1 and NCOR2 were constructed to explore the effects of lncRNA CEBPA-AS1 and NCOR2 on cell proliferation, differentiation, migration, and apoptosis. Finally, tumor formation was measured in nude mice. lncRNA CEBPA-AS1 overexpression or NCOR2 elevation inhibited cell proliferation and migration, and alkaline phosphatase (ALP) and bone gla protein (BGP) activity, while enhancing apoptosis and tumor formation. Furthermore, NCOR2 was elevated in response to lncRNA CEBPA-AS1 overexpression, thus repressing the Notch signaling pathway. Taken together, lncRNA CEBPA-AS1 overexpression inhibits OS progression through diminishing activation of the Notch signaling pathway via upregulating NCOR2. Therefore, lncRNA CEBPA-AS1 may serve as a molecular target for treating OS.
骨肉瘤(OS)是源自原始骨形成间充质细胞的最常见原发性骨恶性肿瘤。长链非编码RNA(lncRNA)表达谱因其与骨肉瘤的关系而受到深入研究。在此,我们阐明lncRNA CEBPA-AS1是否为骨肉瘤细胞中NCOR2的调节因子。基于微阵列的表达分析确定了与骨肉瘤相关的差异表达lncRNA,并预测了与lncRNA和mRNA结合的微小RNA(miR)。发现lncRNA CEBPA-AS1和NCOR2在骨肉瘤组织和细胞中表达较弱。接下来,功能研究表明lncRNA CEBPA-AS1与miR-10b-5p结合以上调NCOR2。随后,构建了lncRNA CEBPA-AS1和NCOR2的基因靶向敲低和过表达重组载体,以探讨lncRNA CEBPA-AS1和NCOR2对细胞增殖、分化、迁移和凋亡的影响。最后,在裸鼠中测量肿瘤形成。lncRNA CEBPA-AS1过表达或NCOR2升高抑制细胞增殖和迁移,以及碱性磷酸酶(ALP)和骨钙蛋白(BGP)活性,同时增强凋亡和肿瘤形成。此外,NCOR2因lncRNA CEBPA-AS1过表达而升高,从而抑制Notch信号通路。综上所述,lncRNA CEBPA-AS1过表达通过上调NCOR2减少Notch信号通路的激活来抑制骨肉瘤进展。因此,lncRNA CEBPA-AS1可能作为治疗骨肉瘤的分子靶点。